Geneticists Hunt for Scleroderma Triggers PDF Print E-mail
Thursday, 29 October 2009 20:50
In all its forms, Scleroderma gives Dartmouth geneticist Michael Whitfield, his graduate students, and his postdoctoral researchers a sense of urgency in their search for the triggers of the chronic condition.

In a study that the Journal of Investigative Dermatology published in its October 2009 edition, Whitfield's team reports a closer connection between a gene profile for the profibrotic pathway TGF-beta and a tendency in some Scleroderma sufferers to develop lung problems.

Jennifer Sargent, who recently earned her Ph.D. in molecular and cellular biology from DMS, is lead author of the study, which analyzed the previously-identified TGF-beta pathway signature in skin biopsies from patients and healthy control subjects from around the country.

"The finding that a gene signature expressed in skin is associated with the occurrence of lung disease is surprising and to our knowledge is previously unreported," the report says. "ILD [interstitial lung disease] is the leading cause of death among patients with dSSc [diffuse systemic sclerosis]. Recent work has developed tools and methods for diagnosis, staging, and characterization of ILD in dSSc patients; however, biomarkers that reliably predict who will develop lung complications before they become symptomatic would be beneficial."

In collaboration with M. Kari Connolly, a professor of dermatology at the University of California-San Francisco, Whitfield, an associate professor of genetics at DMS, and his researchers began creating a map of skin to profile the molecular behavior of genes in scleroderma in 2001.

"Several different pathways likely contribute to the gene expression subsets in scleroderma, and each subset may need to be treated differently," Whitfield says, before adding, "We're getting inquiries from rheumatologists and companies that are looking at drug trials."

For a link to the original article, click here.
 
More articles :

» Dr. Dinesh Khanna Named, "Doctor Of The Year"

The Scleroderma Foundation named Dinesh Khanna, M.D., M.Sc., its 2011 Doctor of the Year during this year's National Patient Education Conference held last month in San Francisco. The award recognizes a skilled physician or researcher for his or her...

» Rheumatologist Receives Scleroderma Foundation's Lifetime Achievement Award

In a recent article, it was reported that ,  Gerald P. Rodnan Professor of Medicine, , received the 's Lifetime Achievement Award in recognition of his service to the community. The award is the foundation's highest honor and is presented to...

» Women and Autoimmunity

50:1, 9:1, 2:1 these are just some ratios of autoimmune disease disparities between women and men. The Society for Women’s Health Research (SWHR) hosted the Capitol Hill briefing, The War Within: Women and Autoimmunity, on Tuesday, October 11 to...

» African Americans Have More Severe Complications From Scleroderma

African Americans have more severe complications from systemic sclerosis, also known as scleroderma, than Caucasians. Findings published today in, , a journal of the American College of Rheumatology (ACR), show that compared with Caucasians,...

» Musculoskeletal Rehabilitation in the Person with Scleroderma

Janet L. PoolePosted: 03/12/2010; Curr Opin Rheumatol. 2010;22(2):205 © 2010 Lippincott Williams & WilkinsAbstractPurpose of Review: The purpose of this review is to examine current evidence for the efficacy of rehabilitation techniques for...

» New Formulation of PAH Medication Is Now Available

Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, is now commercially available, according to the drug's maker, Actelion Pharmaceuticals US, Inc., of South San Francisco, Calif.The product is...